{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Patel KR"],"funding":["Intramural NIH HHS"],"pagination":["540-550"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10782822"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(6)"],"pubmed_abstract":["<h4>Purpose</h4>NCT03253744 was a phase 1 trial to identify the maximum tolerated dose (MTD) of image-guided, focal, salvage stereotactic body radiation therapy (SBRT) for patients with locally radiorecurrent prostate cancer. Additional objectives included biochemical control and imaging response.<h4>Methods and materials</h4>The trial design included 3 dose levels (DLs): 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) in 5 fractions delivered ≥48 hours apart. The prescription dose was delivered to the magnetic resonance- and prostate-specific membrane antigen imaging-defined tumor volume. Dose escalation followed a 3+3 design with a 3-patient expansion at the MTD. Toxicities were scored until 2 years after completion of SBRT using Common Terminology Criteria for Adverse Events, version 5.0, c"],"journal":["Practical radiation oncology"],"pubmed_title":["A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer."],"pmcid":["PMC10782822"],"funding_grant_id":["ZIA BC011552"],"pubmed_authors":["Salerno K","Citrin DE","Choyke P","Schott E","Ning H","Cooley-Zgela T","Huang EP","Patel KR","Turkbey B","Pinto PA","Mena E","Rydzewski NR","Lindenberg L","Cheng J"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.","description":"<h4>Purpose</h4>NCT03253744 was a phase 1 trial to identify the maximum tolerated dose (MTD) of image-guided, focal, salvage stereotactic body radiation therapy (SBRT) for patients with locally radiorecurrent prostate cancer. Additional objectives included biochemical control and imaging response.<h4>Methods and materials</h4>The trial design included 3 dose levels (DLs): 40 Gy (DL1), 42.5 Gy (DL2), and 45 Gy (DL3) in 5 fractions delivered ≥48 hours apart. The prescription dose was delivered to the magnetic resonance- and prostate-specific membrane antigen imaging-defined tumor volume. Dose escalation followed a 3+3 design with a 3-patient expansion at the MTD. Toxicities were scored until 2 years after completion of SBRT using Common Terminology Criteria for Adverse Events, version 5.0, c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov-Dec","modification":"2026-06-02T06:17:22.545Z","creation":"2025-04-04T09:59:10.456Z"},"accession":"S-EPMC10782822","cross_references":{"pubmed":["37442430"],"doi":["10.1016/j.prro.2023.05.012"]}}